ASX - By Stock
|
KZA |
Re:
KZIA - Banter and General Comments
|
|
PT3
|
147 |
51K |
4 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
147
|
51K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Trading Halt
|
|
PT3
|
30 |
10K |
2 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
30
|
10K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Interim data from MSKCC study
|
|
PT3
|
47 |
21K |
4 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
47
|
21K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in substantial holding
|
|
PT3
|
7 |
2.3K |
2 |
24/08/22 |
24/08/22 |
ASX - By Stock
|
7
|
2.3K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
PT3
|
178 |
66K |
5 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
178
|
66K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: GBM Agile Update
|
|
PT3
|
178 |
66K |
4 |
11/08/22 |
11/08/22 |
ASX - By Stock
|
178
|
66K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
PT3
|
71 |
22K |
4 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
71
|
22K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
PT3
|
71 |
22K |
1 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
71
|
22K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
PT3
|
71 |
22K |
2 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
71
|
22K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
PT3
|
71 |
22K |
10 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
71
|
22K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
PT3
|
71 |
22K |
11 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
71
|
22K
|
11
|
|
ASX - By Stock
|
KZA |
Re:
Latest interview
|
|
PT3
|
71 |
22K |
9 |
13/05/22 |
13/05/22 |
ASX - By Stock
|
71
|
22K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
0 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
57
|
17K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
4 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
57
|
17K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
1 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
57
|
17K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
3 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
57
|
17K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
3 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
57
|
17K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
2 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
57
|
17K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
57 |
17K |
7 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
57
|
17K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia establishes ATM program
|
|
PT3
|
42 |
13K |
1 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
42
|
13K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: First patient into Cornell keto study
|
|
PT3
|
18 |
7.3K |
1 |
02/03/22 |
02/03/22 |
ASX - By Stock
|
18
|
7.3K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
77 |
20K |
5 |
04/02/22 |
04/02/22 |
ASX - By Stock
|
77
|
20K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
77 |
20K |
7 |
04/02/22 |
04/02/22 |
ASX - By Stock
|
77
|
20K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
27 |
7.3K |
6 |
07/12/21 |
07/12/21 |
ASX - By Stock
|
27
|
7.3K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Chairman's Address to Shareholders
|
|
PT3
|
22 |
7.3K |
5 |
27/11/21 |
27/11/21 |
ASX - By Stock
|
22
|
7.3K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Kazia Share Price
|
|
PT3
|
791 |
222K |
7 |
26/11/21 |
26/11/21 |
ASX - By Stock
|
791
|
222K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Notification of cessation of securities - KZA
|
|
PT3
|
54 |
12K |
7 |
25/11/21 |
25/11/21 |
ASX - By Stock
|
54
|
12K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
The 3rd Glioblastoma Drug Development Summit
|
|
PT3
|
28 |
6.8K |
5 |
22/11/21 |
22/11/21 |
ASX - By Stock
|
28
|
6.8K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
The 3rd Glioblastoma Drug Development Summit
|
|
PT3
|
28 |
6.8K |
9 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
28
|
6.8K
|
9
|
|
ASX - By Stock
|
KZA |
Re:
The 3rd Glioblastoma Drug Development Summit
|
|
PT3
|
28 |
6.8K |
3 |
19/11/21 |
19/11/21 |
ASX - By Stock
|
28
|
6.8K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Maybe
|
|
PT3
|
18 |
3.8K |
0 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
18
|
3.8K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Maybe
|
|
PT3
|
18 |
3.8K |
6 |
17/11/21 |
17/11/21 |
ASX - By Stock
|
18
|
3.8K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
SNO 26th Annual Meeting
|
|
PT3
|
123 |
36K |
4 |
16/11/21 |
16/11/21 |
ASX - By Stock
|
123
|
36K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
SNO 26th Annual Meeting
|
|
PT3
|
123 |
36K |
7 |
15/11/21 |
15/11/21 |
ASX - By Stock
|
123
|
36K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
PT3
|
2.0K |
630K |
10 |
01/11/21 |
01/11/21 |
ASX - By Stock
|
2.0K
|
630K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
PI3K/mtor inhibition effects against COVID-19
|
|
PT3
|
7 |
2.5K |
2 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
7
|
2.5K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
PI3K/mtor inhibition effects against COVID-19
|
|
PT3
|
7 |
2.5K |
3 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
7
|
2.5K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
PI3K/mtor inhibition effects against COVID-19
|
|
PT3
|
7 |
2.5K |
5 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
7
|
2.5K
|
5
|
|
ASX - By Stock
|
KZA Biotech |
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
|
|
PT3
|
0 |
292 |
3 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
0
|
292
|
3
|
|
ASX - By Stock
|
KZA Biotech |
Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma:
|
|
PT3
|
0 |
361 |
8 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
0
|
361
|
8
|
|
ASX - By Stock
|
KZA Biotech |
Is autism trial on the horizon?
|
|
PT3
|
0 |
325 |
4 |
10/10/21 |
10/10/21 |
ASX - By Stock
|
0
|
325
|
4
|
|
ASX - By Stock
|
KZA |
Re:
How does GBM AGILE work?
|
|
PT3
|
73 |
25K |
7 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
73
|
25K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
KZA
|
|
PT3
|
8 |
2.9K |
3 |
07/09/21 |
07/09/21 |
ASX - By Stock
|
8
|
2.9K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in Directors interests
|
|
PT3
|
16 |
4.6K |
2 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
16
|
4.6K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in Directors interests
|
|
PT3
|
16 |
4.6K |
7 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
16
|
4.6K
|
7
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Change in Directors interests
|
|
PT3
|
16 |
4.6K |
10 |
30/08/21 |
30/08/21 |
ASX - By Stock
|
16
|
4.6K
|
10
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
PT3
|
2.0K |
630K |
4 |
27/08/21 |
27/08/21 |
ASX - By Stock
|
2.0K
|
630K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
PT3
|
27 |
7.3K |
5 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
27
|
7.3K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
PT3
|
2.0K |
630K |
5 |
28/07/21 |
28/07/21 |
ASX - By Stock
|
2.0K
|
630K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
KZA Media Thread
|
|
PT3
|
2.0K |
630K |
0 |
10/07/21 |
10/07/21 |
ASX - By Stock
|
2.0K
|
630K
|
0
|
|